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Conclusions: A fast re-evaluation of the dose distribution 
using small FOV CBCT data is feasible in lung cancer patients. 
The use of patient-specific HU-to-density tables significantly 
improves the accuracy of these dose calculations. Only three 
of the 13 patients needed to be replanned to ensure 
sufficient target coverage.  
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Purpose/Objective: To quantify the influence of different 
IGRT alignment techniques on geometrical and dosimetrical 
consequences for proton irradiation of prostate cancer under 
consideration of actual occurring interfractional changes in a 
prospective patient positioning study. 
Materials and Methods: Ten prostate cancer patients, 
treated with photons, were positioned according to an in-
house protocol for proton therapy including the application of 
water-filled rectum balloons. A series of computed 
tomography data with 10-18 (median 15) in-room control CT 
scans per patient was acquired on different treatment days 
during the 8 week treatment for IGRT. Initial proton therapy 
plans were generated on the pre-treatment CT using passive 
field formation with two lateral fields. Planning was done on 
the CTV taking into account beam delivery uncertainties in 
the field-specific hardware. For evaluation purposes a PTV 
was created (CTV+5 mm/4 mm dorsal). Based on the control 
CTs, two different patient alignment approaches were 
simulated using rigid image registration: (a) Matching of the 
pelvic bony anatomy (BAM) and (b) Matching based on 
implanted marker seeds (MSM). For both approaches, the 
dose distribution per fraction and the accumulated dose 
distribution were evaluated. For dose accumulation non-rigid 
deformable image registration of the control CTs with the 
planning CT was applied. 
Results: The preliminary evaluation (7 of the 10 patients) 
revealed in general an advantage of the bony anatomy 
matching concerning target coverage. In all patients BAM 
target coverage was either better or similar compared to 
MSM. Aligning based on the bony anatomy (BAM) resulted in a 
mean displacement of the CTV center of 0.5 mm, -1.2 mm 
and -2.3 mm in the LR-, AP- and SI-direction, respectively. 
The mean Euclidean shift was 3.4 mm, hence substantially 
smaller than the CTV-PTV margin of 5 mm and comparable to 
MSM (3.0 mm). Based on the control CTs, on average only 2 
ml of the CTV (<2%) were outside of the original PTV for both 
BAM and MSM. Dosimetric evaluation of the accumulated dose 
distributions revealed a reduction of the CTV V95% relative to 
the planning CT of 1.6% and 2.1% for BAM and MSM, 
respectively. Analogously, the PTV V90% was reduced by 3.2% 
(BAM) and 4.5% (MSM). Moreover, for MSM the CTV minimum 
dose was reduced to a larger extent compared to BAM (on 
average -20% vs. -14%). The mean dose for rectum and 
bladder changed relative to the initial treatment plan on 
average by 12.1% and -15.2% for BAM and 9.5% and -4.9% for 
MSM, respectively.  
 
 
 
Conclusions: From the preliminary results it can be 
concluded that for proton therapy patient positioning based 
on bony anatomy is altogether superior to the marker 
matching leading to adequate dose distributions for both 
target and organs at risks. The applied uncertainty margins 
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appeared sufficient for BAM. The slightly inferior results on 
target coverage for MSM are likely due to the variations of 
the femoral head positions influencing proton range and dose 
distribution. 
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Purpose/Objective: Patients with head and neck cancer can 
experience considerable tumour shrinkage during their 
treatment course which in turn can lead to alterations of the 
planned dose distribution. In this study we evaluate and 
compare the robustness of standard and dose-painted plans 
in presence of extensive tumour shrinkage. 
Materials and Methods: Eleven patients with extensive in-
treatment tumour shrinkage (mean shrinkage 87.2 cm^3) 
were selected for this retrospective study. The patients 
underwent 3 to 5 CT scans during their course of 
radiotherapy (RT). Two planning strategies were simulated on 
this dataset using VMAT: 1) standard integrated boost plans 
delivering a uniform dose of 2 Gy x 34 to the tumor PTV and 
2) a data-driven dose-painting protocol (CONTRAST), in which 
five different dose levels are given, with the 18F-
fludeoxyglucose PET-positive region receiving 2.35 Gy x 34.  
An expert radiation oncologist manually contoured the GTV 
on all in-treatment scans, to which the plans were then 
transferred and recalculated. The GTV volume as well as the 
dose to the spinal cord and the mandible were reported. 
Using the Wilcoxon matched pairs signed rank test we tested 
the hypothesis that tumour shrinkage causes significant dose 
increase to the spinal cord and the mandible. Finally we 
investigated if there was any significant difference in dose 
increase to these OAR's between the standard protocol and 
the CONTRAST protocol. 
Results: A significant in-treatment dose-increase was found 
in the spinal cord (p < 0.003) of 1.1 Gy +/-0.9 Gy (median +/- 
interquartile range) using the standard protocol and 1.2 Gy 
+/- 1.6 Gy using the CONTRAST protocol (illustrated in figure 
1, bottom). The increase in spinal cord dose was not 
statistically different between the two planning strategies 
(P=0.77). 
In the mandible a dose increase of 0.5 Gy +/- 0.8 Gy using 
standard plans and 1.35 Gy +/- 1.6 Gy using CONTRAST-plans 
was found. For patients with a PET-positive volume close to 
the mandible, the dose constraint to this OAR was clearly 
violated, as illustrated in figure 1 (top).  
 
 
 
Conclusions: Tumour shrinkage had a statistically significant 
impact on the delivered doses to the spinal cord and the 
mandible. The dose increase found is modest in both organs 
in spite of considerable tumour shrinkage. Standard plans and 
dose-painted plans created using the CONTRAST protocol are 
equally robust with regard to the spinal cord and the increase 
in dose is probably clinically irrelevant. Standard plans 
appear more robust than CONTRAST plans with regard to the 
mandible, due to high dose boosting of regions close to the 
OAR (see figure 1). For cases where large tumours are in 
proximity of an important OAR and a large tumour shrinkage 
is observed, an adaptive strategy may be necessary. 
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Purpose/Objective: To use cone beam computed tomography 
(CBCT) images for reliable and robust proton dose and range 
calculations. Scatter induced reconstruction errors are the 
dominant artifacts affecting CBCT HU accuracy. In order to 
generate a CBCT image for reliable dose and range 
calculations, scatter effects must be removed. 
Materials and Methods: Two common scatter correction 
methods were tested: uniform scatter model and a priori CT 
based scatter generation. Images were acquired for a 
electron density calibration phantom, multiple 
anthropomorphic phantoms, and patients selected from 
multiple treatment locations including cranial, prostate, and 
thoracic. For the phantom studies the diagnostic CT was 
considered to be the gold standard for dose and range 
calculations. For the patient studies, all daily comparisons 
